Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
HERA trial continues to demonstrate significant patient benefits from Herceptin

HERA trial continues to demonstrate significant patient benefits from Herceptin

Etanercept and chemo might reduce fatigue in cancer patients

Etanercept and chemo might reduce fatigue in cancer patients

New approach to treating breast cancer uses existing chemo drug

New approach to treating breast cancer uses existing chemo drug

Prostate cancer research may be faster with prostate-specific antigen endpoints

Prostate cancer research may be faster with prostate-specific antigen endpoints

Phenoxodiol - docetaxel combination for women with recurrent ovarian cancer

Phenoxodiol - docetaxel combination for women with recurrent ovarian cancer

Substance found in evening primrose oil inhibits breast cancer gene

Substance found in evening primrose oil inhibits breast cancer gene

DN-101 may protect against major side effects of chemotherapy

DN-101 may protect against major side effects of chemotherapy

Targeted drug delivery now possible using nanoparticle-apatamer conjugates

Targeted drug delivery now possible using nanoparticle-apatamer conjugates

Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates

Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates

The CMS demonstration project in oncology

The CMS demonstration project in oncology

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Chemo combo increases breast cancer survival

Chemo combo increases breast cancer survival

Breast cancer chemotherapy regimen associated with life-threatening complications

Breast cancer chemotherapy regimen associated with life-threatening complications

Doxorubicin-docetaxel combination is associated with an increased risk of severe and life-threatening complications

Doxorubicin-docetaxel combination is associated with an increased risk of severe and life-threatening complications

Vitamin D, taxotere combination promising for advanced prostate cancer

Vitamin D, taxotere combination promising for advanced prostate cancer

Antibody combined with cancer drug shows promise against breast tumors

Antibody combined with cancer drug shows promise against breast tumors

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Tarvacin equivalent plus Docetaxel inhibits breast tumor growth by 93%

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Taxotere shows significant survival benefit in the treatment of advanced gastric cancer

Drug trio increases survival rate in head and neck cancers

Drug trio increases survival rate in head and neck cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.